Genitourinary Cancers Symposium (ASCO GU) | Conference

Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence

February 20th 2022

The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.

Adjuvant Pembrolizumab Maintains DFS Benefit in High-Risk RCC

February 20th 2022

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

Dr. Choueiri on the Follow-Up Analysis of KEYNOTE-564 in RCC

February 19th 2022

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Superior Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC

February 19th 2022

At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.

Lenvatinib Plus Pembrolizumab Produces Consistent Efficacy in East Asian Subset With Advanced RCC

February 19th 2022

The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.

Immune Cell–Related Parameters May Serve as Biomarkers for Response to Nivolumab/Ipilimumab in Clear Cell RCC

February 19th 2022

Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma.

Frontline Nivolumab/Cabozantinib Combo Maintains Long-Term OS Benefit in RCC

February 19th 2022

The combination of nivolumab plus cabozantinib elicited a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma.

Cabozantinib Dose Reduction Improves Survival in Patients With mRCC

February 19th 2022

A reduction in cabozantinib dosage because of toxicity demonstrated improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

Long-Term Data Show That Tivozanib Continues to Be Superior Vs Sorafenib in mRCC

February 19th 2022

Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.

Frontline Tivozanib Is Effective, Safe in Real-World Treatment of mRCC

February 19th 2022

Frontline tivozanib was noninferior to other tyrosine kinase inhibitors for the treatment of patients with metastatic renal cell carcinoma in a real-world setting.

Lenvatinib/Pembrolizumab Combo Effective in Advanced RCC, Regardless of Biomarker Status

February 19th 2022

Treatment with lenvatinib plus pembrolizumab was associated with a clinical benefit in advanced renal cell carcinoma, regardless of a patient’s biomarker status.

Second-Line Cabozantinib Produces Similar Outcomes in RCC, Regardless of Frontline Immunotherapy Choice

February 19th 2022

Treatment with cabozantinib (Cabometyx, Cometriq) in the second-line setting generated similar time-to-event end points and response rates in patients with advanced renal cell carcinoma, regardless of frontline immune-oncology combinations.

Neoadjuvant Enfortumab Vedotin Demonstrates Encouraging Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

February 19th 2022

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

Frontline Olaparib/Durvalumab Misses PFS End Point in Platinum-Ineligible Metastatic Urothelial Carcinoma

February 19th 2022

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

Addition of Sacituzumab Govitecan to Pembrolizumab Produces Promising Antitumor Activity in Metastatic Urothelial Cancer

February 19th 2022

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Cabozantinib After Immunotherapy Failure Reassured as Safe, Feasible for mRCC

February 19th 2022

Updated data support the common use of cabozantinib in this setting without new safety signals in patients with metastatic renal cell carcinoma.

FDG and NaF PET/CT Imaging Prognostic for OS in Metastatic GU Cancers Treated With Cabozantinib/Nivolumab Combos

February 18th 2022

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.

Niraparib Plus Cabozantinib Shows Early Promise in Advanced Urothelial and Kidney Cancer

February 18th 2022

Niraparib in combination with cabozantinib demonstrated a manageable safety profile, with preliminary efficacy observed in heavily pretreated patients with metastatic urothelial carcinoma.

Dr. Petrylak on the Utilization of Enfortumab Vedotin in MIBC

February 18th 2022

Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).

Dr. Iacovelli on Efficacy Findings From the ARIES Trial in Urothelial Cancer

February 18th 2022

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.